Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

Gilead Sciences Inc. and the federal government settled a patent-infringement case in which the US sought $1 billion from the ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...

Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...

UNAIDS urges speed and compassion urging pharmaceutical companies to enable access to new, life-saving medicinesDAVOS/GENEVA, ...

Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January ...

Cognizant and Gilead expand partnership to drive greater value through advanced technology applications: Teaneck, New Jersey Friday, January 31, 2025, 14:00 Hrs [IST] Cognizant ha ...